Abstract
LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have